Keytruda And Small Cell Lung Cancer

The immunotherapy agent keytruda pembrolizumab had an overall response rate orr of 33 percent in a recent trial including patients with extensive stage small cell lung cancer sclc.

Keytruda and small cell lung cancer.

The supplemental biologics license application based on results from the phase 1b keynote 028 trial nct02054806 and the ongoing keynote 158 phase 2. Food and drug administration has accepted merck s application seeking accelerated approval of keytruda pembrolizumab for the treatment of advanced small cell lung cancer sclc patients who failed at least two prior therapies. Keytruda may be used with the chemotherapy medicines pemetrexed and a platinum as your first treatment when your lung cancer has spread advanced nsclc and is a type called nonsquamous and your tumor does not have an abnormal egfr or alk gene. Keytruda pembrolizumab is used to treat advanced melanoma non small cell lung cancer small cell lung cancer head and neck squamous cell carcinoma classical hodgkin lymphoma primary mediastinal large b cell lymphoma urothelial carcinoma microsatellite instability high cancer gastric cancer esophageal cancer cervical cancer hepatocellular carcinoma merkel cell carcinoma renal cell.

On june 17 2019 the food and drug administration granted accelerated approval to pembrolizumab keytruda merck for patients with metastatic small cell lung cancer sclc with disease.